Achelios Therapeutics United States

Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Website:
Achelios.com
Company Size (Fulltime employees)
Year of foundation
2012
Partnering Objectives
Please specify your partnering goal
1. License OTC and RX product ex -US , Asia and EU
Headquartner in China
Assets Information 1
OTC1% diclofenac|Topical NSAID|pain and inflamation|global
Assets Information 2
Prescription 3% Diclofenac|Topical NSAID|Acute and chronic pain, opioid spearing|global
Assets Information 3
5%& 3% Ketoprofen topical|Topical Ketoprofen gel|Migraine, TMJD , Chronic pain|global
Biotech/Pharma Asset Stage
Dr. Crist Frangakis
President & ceo 
Functionality

Adragos Pharma Germany

Private equity firm
Company Size (Fulltime employees)
Please specify your partnering goal
Both raising further funds and driving deal pipeline
Headquartner in China
Mr. Andreas Raabe
Partner 
Functionality

Allakos United States

Allakos is a public-traded clinical-stage biopharmaceutical company developing first-in-class antibody-based therapeutics to treat allergic and inflammatory diseases.
Website:
www.allakos.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Tan Jenen
Tan Jenen
LinkedIn logo Sr Manager, Market Planning 

Bayer Healthcare China

Bayer Healthcare
Dr. Min Pang
Alliance Manager 

Beijing Continent Pharmaceutical Co., Ltd. China

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Qin Li
Associate Director,Business Development 

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Nan Bing
CEO 
Functionality

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

Elasmogen Ltd United Kingdom

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Licensing of existing assets and co-development of new therapeutic development
Headquartner in China
Dr. Caroline Barelle
CEO 

Enzymogen Israel

Enzymogen is a biotechnology company developing cannabinoids in algae as new drug entities.
Main activities:
Development of a platform for producing API cannabinoids based on proprietary technology (not plant extracts);
Develop cannabinoids as drugs for unmet clinical needs.

Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
Fundraising; partnering; product co-development
Headquartner in China
Assets Information 1
Enzymogen Ltd|Cannabinoids production in microalgae|CNS diseases, Onclology|US, EU, Can, Jap, Chi
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 145.13KB)
Mr. Meir Azulay
Director 
Functionality